Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Breast Neoplasms 7Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Multiple Myeloma 4Lymphoma 4Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Hereditary Sensory and Autonomic Neuropathies 2Hematologic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1

Interventions

Docetaxel 277Prednisone 237enzalutamide 177Leuprolide 172Radiotherapy 164Abiraterone Acetate 154Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 79abiraterone 77gallium 68 PSMA-11 74Specimen Handling 67darolutamide 58Gonadotropin-Releasing Hormone 58Radiation 56Triptorelin Pamoate 53cabazitaxel 50Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × sapanisertib × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡